Talking Rheumatology Research

In this episode, recorded live at BSR25, Professor Robert J Moots joins Professor Ernest Choy to discuss their article reporting on a randomized, controlled, head-to-head clinical trial comparing the two most frequently used biologics in active refractory Behçet’s. Listen now to hear the findings and what this means for future clinical practice! Further reading: You can read this article [https://doi.org/10.1093/rheumatology/keae585] in Rheumatology. Thanks for listening to T...

How can we identify modifiable risk factors and new therapeutic targets in polymyalgia rheumatica? In this episode, recorded live at BSR25, Prof Ernest Choy and Dr Steven Zhao discuss Steven's genome-wide meta-analysis and Mendelian randomisation study. They cover the key findings, which include some novel loci and potential therapeutic targets for PMR, as well as the hallmarks of a good Mendelian randomisation study. Further reading: Read Steven's full study in Rheumatology Thanks for...

How can we improve time from symptom onset to axSpA diagnosis? In this episode, Dr Fabian Proft talks to Dr Antoni Chan about his fantastic work to reduce time to diagnosis in axial spondyloarthritis (axSpA) using an integrated referral and education system. They discuss the importance of a multi-pronged approach to education, as well as how clinicians might start improving time to axSpA diagnosis in their own settings. Further reading: Read Antoni's full article in Rheumatology A...

Should there be distinct definitions for difficult-to-treat and complex-to-manage psoriatic arthritis? In this episode of Talking Rheumatology Research, Dr Fabian Proft and Dr Andre Ribeiro join Dr Ai Lyn Tan to discuss their work to define difficult-to-treat psoriatic arthritis, as part of GRAPPA's wider D2T-PsA project. Find out more: Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals ...

Dr. Vanessa Quick joins Dr. Ernest Choy to discuss her recent article on the impact of qwTCZ cessation on GCA patients. Looking at relapse rates and key risk factors, this discussion highlights the need for improving access to care and treatment for GCA patients, including increasing disease awareness, faster referral to specialised care, better access to diagnostic tools, and a multidisciplinary approach to managing this condition. You can read this article [https://doi.org/10.1093/rhe...